Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTIS2022-502814-99-00
CTIS2022-502814-99-00Active, not recruitingPhase 1

A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tablet Formulations of Lazertinib

Janssen - Cilag International0 sites72 target enrollmentStarted: March 7, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
72
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Ages
18 to 64 (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Investigators

Similar Trials

Completed
Phase 1
Food effect and pharmacokinetics study in healthy, male volunteers with P2202
CTRI/2010/091/002992Piramal Enterprises Limited32
Active, not recruiting
Phase 1
A study in healthy volunteers to look at how the test medicine, COMP360, is taken up by the body when given as two different strength capsulesTreatment-resistant depression
ISRCTN16636661COMPASS Pathfinder Limited14
Completed
Not Applicable
A phase 1, open-label, randomized, 2-period, 2-sequence, crossover study to evaluate the bioequivalence of Bosutinib pediatric capsule and the commercial tablet formulations in healthy participants under fed conditiochronic myeloid leukemia10024324
NL-OMON49458Pfizer, Inc.66
Active, not recruiting
Phase 1
A two part Open-Label, Randomized, Phase II/III clinical study to examine how safe and how well Dinutuximab works on it’s own or in combination with Irinotecan when treating patients with small cell lung cancer that is unresponsive or no longer responding to previous treatmentrelapsed or refractory small cell lung cancer (SCLC)MedDRA version: 21.1Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-000758-20-SKnited Therapeutics Corporation485
Active, not recruiting
Phase 1
A two part Open-Label, Randomized, Phase II/III clinical study to examine how safe and how well Dinutuximab works on it’s own or in combination with Irinotecan when treating patients with small cell lung cancer that is unresponsive or no longer responding to previous treatmentrelapsed or refractory small cell lung cancer (SCLC)MedDRA version: 20.0Level: PTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-000758-20-PLnited Therapeutics Corporation470